Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan
Phenotypic screening has identified small-molecule modulators of aging, but the mechanism of compound action often remains opaque due to the complexities of mapping protein targets in whole organisms. Here, we combine a library of covalent inhibitors with activity-based protein profiling to coordinately discover bioactive compounds and protein targets that extend lifespan in Caenorhabditis elegans. We identify JZL184-an inhibitor of the mammalian endocannabinoid (eCB) hydrolase monoacylg-lycerol lipase (MAGL or MGLL)-as a potent inducer of longevity, a result that was initially perplexing as C. elegans does not possess an MAGL ortholog. We instead identify FAAH-4 as a principal target of JZL184 and show that this enzyme, despite lacking homology with MAGL, performs the equivalent metabolic function of degrading eCB-related monoacylglycerides in C. elegans. Small-molecule phenotypic screening thus illuminates pure pharmacological connections marking convergent metabolic functions in distantly related organisms, implicating the FAAH-4/monoacylglyceride pathway as a regulator of lifespan in C. elegans.
Chen, Alice L., Kenneth M. Lum, Pablo Lara-Gonzalez, et al. 2019. "Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan." Nature Chemical Biology 15(5): 453-462.
Nature Publishing Group
Nature Chemical Biology
Chemistry and Biochemistry
Molecular characterization, Endocannabinoid system, Caenorhabdits-Elegans, Stem-cells, Longevity, Lipase, Enzyme, Identification, Biosynthesis, Cannabinoids